top of page

Louisiana Lawmakers Approve Medical Marijuana Expansion Bill In Committee

  • Writer: Bob Marley
    Bob Marley
  • Apr 28, 2022
  • 3 min read

“We are missing out on golden opportunities in this state to build a gateway to better roads, bridges and schools.”

By Victor Skinner | The Center Square

A bill to shift authority over medical marijuana and expand cultivation in Louisiana has gained approval from the House Committee on Health and Welfare.

Committee members voted unanimously to approve House Bill 566, sponsored by Rep. Larry Bagley (R), to shift licensure and regulation authority over the state’s medical marijuana program from the Louisiana Department of Agriculture and Forestry to the Louisiana Department of Health.

The bill passed on Wednesday would also remove the limit of two production licenses in the state, which are currently granted to the agricultural centers at Louisiana State University and Southern University.

“My bill would change the regulation of the medical marijuana industry from the ag department to LDH, and we had several meeting with LDH and the ag department to make sure that would be ok, and for the additional growers,” Bagley said.

Kevin Caldwell is the southeast legislative manager for the Marijuana Policy Project. He put Louisiana’s current medical marijuana market in perspective for committee members.

“Let’s look to see what our neighbors are doing,” he said. “In Arkansas, a state that has over 1 million less citizens than… Louisiana, they have eight growers. The state of Florida has 22 growers. Oklahoma, which has no caps, has well over 1,000 growers. Missouri has 60 growers. The state of Mississippi adopted a medical cannabis program this year and they put no caps on the number of growers in their program.”

“So if we’re looking to see how our neighbors are proceeding with medical cannabis, I think that it’s important to see the fact that we have a lot more than two growers in all of our neighboring states.”

More growers equals cheaper product, Caldwell said, with competition resulting in prices about 40 percent cheaper than in Louisiana.

Others who testified criticized the presidents of the companies currently supplying the state’s medical marijuana market for advocating against expansion. They argue the monopoly is making products unaffordable for patients.

“The people that are running it right now are just here to make money,” said Angela Broussard, a medical marijuana patient. “People who are coming off of opioid dependency are looking back to opioids right now, because that’s $3 a month. And this is ridiculous.”

Gary Chambers, a candidate for the U.S. Senate who recently smoked marijuana in a campaign ad, discussed how other states are leveraging medical marijuana for the public good, and how Louisiana’s slow rollout of its program, approved by lawmakers in 2015, is putting the state at a disadvantage.

“We are missing out on golden opportunities in this state to build a gateway to better roads, bridges and schools and this committee has the capacity to help us expand that industry,” he said.

Other medical marijuana patients testified about how the current program is resulting in supply shortages and increasing prices, which run about $400 a month for a prescription tincture to treat conditions like epilepsy, spasm disorders, cancer, Crohn’s disease and others.

Jeff Schmidtke, executive director of BioSciences Louisiana, a company pursuing a cultivation license, stressed that expanding the program will “benefit everyone.”

“More growers alleviate the pressure of stocking empty shelves and allow for more product to be dedicated to doctors, scientists, professors, students and deans of research for all hospital systems across the state,” he said.

HB 566 mirrors many aspects of HB 697, sponsored by House Speaker Pro Tempore Tanner Magee (R), that was approved by the House Health and Welfare Committee last week. Magee’s bill also expands the number of pharmacies licensed to sell prescription marijuana and would allow for home delivery.

Another marijuana bill sponsored by Rep. Joe Marino (I), HB 135, to allow the sale of medical marijuana to certain qualifying out-of-state patients also cleared the full House on Wednesday with a vote of 72-22.

This story was first published by The Center Square.

Bankers Associations From All 50 States Push Senate To Pass Marijuana Banking Reform As Part Of Large-Scale Bill

Photo courtesy of Nicholas C. Morton.

Comments


Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page